+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cytomegalovirus Treatment Drugs Market - Global Forecast to 2030- Product Image
Cytomegalovirus Treatment Drugs Market - Global Forecast to 2030- Product Image
New

Cytomegalovirus Treatment Drugs Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6085276
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Cytomegalovirus (CMV) poses a significant clinical challenge, particularly among immunocompromised patients such as transplant recipients and those with HIV/AIDS. With advances in antiviral development and immunotherapy, the therapeutic landscape has evolved rapidly over the past decade. Novel nucleoside and non-nucleoside analogues have complemented traditional intravenous immunoglobulins and monoclonal antibody approaches, creating a multi-pronged defense against primary infections and reactivation events. Decision-makers across pharmaceutical organizations are navigating complex regulatory pathways, supply chain intricacies, and reimbursement pressures while striving to meet the rising demand for safe, effective CMV prophylaxis and treatment. This summary distills the critical market dynamics, competitive forces, and strategic imperatives shaping the industry today, equipping stakeholders with the insights needed to seize emerging opportunities and address unmet needs.

Transformative Shifts Reshaping CMV Therapeutic Strategies

The CMV treatment arena is undergoing transformative shifts driven by breakthroughs in drug design, precision medicine, and patient monitoring. Gene-editing platforms now inform the development of compounds that specifically target viral replication machinery, reducing off-target effects. Personalized dosing regimens leveraged by real-time biomarkers are replacing one-size-fits-all protocols in preemptive therapy. In parallel, immunoglobulin formulations have become more refined, with next-generation monoclonal antibodies offering higher affinity and extended half-lives, enabling less frequent dosing. Digital health tools-ranging from remote viral load tracking to AI-powered adherence support-are redefining patient engagement. Together, these shifts are collapsing the gap between prophylaxis and therapeutic interventions, ushering in an era where early detection, targeted therapy, and long-term immune modulation converge to improve outcomes.

Assessing the Cumulative Impact of 2025 US Tariffs on CMV Drugs

In 2025, newly imposed United States tariffs on active pharmaceutical ingredients and finished formulations have reverberated throughout the global CMV supply chain. Manufacturers sourcing nucleoside analogues and advanced immunoglobulins from overseas facilities have faced cost escalations, prompting several to relocate manufacturing lines stateside to mitigate duties. This onshore shift has, however, strained domestic capacity and driven up lead times for critical monoclonal antibody reagents. End-users, from hospital systems to specialty pharmacies, are experiencing incremental price pressures that could influence formulary decisions in prophylaxis programs. Simultaneously, companies are renegotiating supplier agreements and exploring tariff-exempt free trade zones to preserve margin integrity. Collectively, these adaptations underscore the tariff regime’s role in accelerating supply chain diversification and reinforcing localized production as a strategic priority.

Key Segmentation Insights Across CMV Treatment Modalities

A granular view of the CMV market emerges when mapping the industry across product type, treatment type, patient demographics, and distribution channel. On the product front, antiviral drugs divide into non-nucleoside and nucleoside analogues, each offering distinct safety and efficacy profiles, while immunoglobulins split between intravenous formulations and targeted monoclonal antibodies. Treatment paradigms bifurcate into prophylaxis-where clinicians choose between preemptive therapy guided by viral load thresholds or universal prophylaxis for high-risk cohorts-and therapeutic regimens that address acute episodes and sustain remission through maintenance dosing. Patient segmentation further refines strategy: adult populations break down into immunocompetent individuals and immunocompromised hosts, the latter encompassing both HIV/AIDS and organ transplant patients, whereas pediatric cases range from infants to neonates with immature immune defenses. Finally, the market’s distribution architecture spans hospital pharmacies managing in-house infusions, online pharmacies facilitating direct-to-home shipping, and retail outlets stocking oral antivirals. Intersecting these dimensions reveals where unmet needs are most acute and which channels offer the fastest routes to patient access.

Regional Insights Driving CMV Treatment Adoption and Access

Regional dynamics exert a profound influence on CMV drug adoption, regulatory complexity, and payer structures. In the Americas, streamlined regulatory pathways and established transplant networks support rapid uptake of novel nucleoside analogues, though pricing pressures from public and private payers necessitate robust health economics data. Europe, Middle East & Africa presents a heterogeneous mosaic: Western Europe favors high-cost immunoglobulin therapies backed by centralized HTA assessments, while markets in Eastern Europe and parts of the Middle East balance affordability concerns with growing transplant volumes; African markets remain nascent but show potential through donor-funded programs. Asia-Pacific sits at the forefront of biologics innovation, with key manufacturing hubs in China and India ramping up monoclonal antibody production, even as national reimbursement schemes evolve to include advanced antiviral regimens. Together, these regional patterns highlight where strategic investments, localized clinical trials, and partnerships can drive market penetration and patient benefit.

Strategic Company Movements Shaping the Competitive Arena

Industry leaders are forging alliances and pursuing R&D that align with evolving clinical needs. AbbVie Inc. and Gilead Sciences, Inc. focus on next-generation nucleoside analogues designed for renal safety, while Astellas Pharma Inc. and Merck & Co., Inc. advance preemptive therapy platforms augmented by digital diagnostics. F. Hoffmann-La Roche Ltd and GlaxoSmithKline plc are leveraging their monoclonal antibody portfolios to explore extended-interval prophylaxis, and Pfizer Inc. is investigating combination regimens that pair immunoglobulins with small-molecule inhibitors for synergistic viral suppression. Emerging biotechs like AiCuris Anti-infective Cures GmbH and AlloVir, Inc. are pioneering novel mechanisms of action, whereas Moderna Therapeutics, Inc. applies mRNA technology to elicit virus-specific immune responses. Basilea Pharmaceutica Ltd., Chimerix, Inc., Takeda Pharmaceutical Company Limited, Vistide Pharmaceuticals Inc., and Vical Incorporated round out a competitive field characterized by platform differentiation, strategic licensing, and geographic expansion. This constellation of players underscores the sector’s collaborative ethos and the breadth of innovation underway.

Actionable Recommendations for CMV Treatment Industry Leaders

To navigate this complex landscape, industry leaders should prioritize targeted R&D investments in both novel small molecules and biologics, ensuring portfolios address unmet patient needs in high-risk cohorts. Establishing flexible manufacturing footprints that incorporate tariff-exempt zones and regional fill-finish sites will bolster supply resilience. Collaboration with digital health providers to integrate remote monitoring tools can enhance adherence and enable data-driven decision-making for preemptive therapy. Forging partnerships with regional distribution networks and specialty pharmacies will optimize patient access, particularly in emerging markets. Additionally, investing in comprehensive health economics and outcomes research will strengthen reimbursement dossiers, facilitating coverage across diverse payer systems. By aligning portfolio strategy, manufacturing agility, and digital innovation, organizations can secure competitive advantage and deliver sustainable value to patients and stakeholders alike.

Conclusion: Unifying Innovation and Strategy in CMV Management

The CMV treatment ecosystem stands at a crossroads of scientific innovation, regulatory evolution, and market realignment. Success will hinge on the ability to translate cutting-edge research into scalable therapies, manage geopolitical and economic headwinds, and tailor solutions to diverse patient populations. Leaders who embrace an integrated approach-melding R&D excellence, adaptive supply chains, strategic partnerships, and digital engagement-will shape the future standard of care. As the industry converges on precision prophylaxis and long-term viral suppression, proactive planning and collaborative execution will determine which organizations emerge as the definitive authorities in CMV management.

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Treatment Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Antiviral Drugs
    • Non-Nucleoside Analogues
    • Nucleoside Analogues
  • Immunoglobulins
    • Intravenous Immunoglobulins (IVIG)
    • Monoclonal Antibodies
  • Prophylaxis
    • Preemptive Therapy
    • Universal Prophylaxis
  • Therapeutic
    • Acute Treatment
    • Maintenance Therapy
  • Adult
    • Immunocompetent
    • Immunocompromised
      • HIV/AIDS Patients
      • Transplant Patients
  • Pediatric
    • Infants
    • Neonates
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

This research report categorizes the Cytomegalovirus Treatment Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Cytomegalovirus Treatment Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • AiCuris Anti-infective Cures GmbH
  • AlloVir, Inc.
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Chimerix, Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna Therapeutics, Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited
  • Vical Incorporated
  • Vistide Pharmaceuticals Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cytomegalovirus Treatment Drugs Market, by Product Type
8.1. Introduction
8.2. Antiviral Drugs
8.2.1. Non-Nucleoside Analogues
8.2.2. Nucleoside Analogues
8.3. Immunoglobulins
8.3.1. Intravenous Immunoglobulins (IVIG)
8.3.2. Monoclonal Antibodies
9. Cytomegalovirus Treatment Drugs Market, by Treatment Type
9.1. Introduction
9.2. Prophylaxis
9.2.1. Preemptive Therapy
9.2.2. Universal Prophylaxis
9.3. Therapeutic
9.3.1. Acute Treatment
9.3.2. Maintenance Therapy
10. Cytomegalovirus Treatment Drugs Market, by Patient Type
10.1. Introduction
10.2. Adult
10.2.1. Immunocompetent
10.2.2. Immunocompromised
10.2.2.1. HIV/AIDS Patients
10.2.2.2. Transplant Patients
10.3. Pediatric
10.3.1. Infants
10.3.2. Neonates
11. Cytomegalovirus Treatment Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Americas Cytomegalovirus Treatment Drugs Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Cytomegalovirus Treatment Drugs Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Cytomegalovirus Treatment Drugs Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. AiCuris Anti-infective Cures GmbH
15.3.3. AlloVir, Inc.
15.3.4. Astellas Pharma Inc.
15.3.5. Basilea Pharmaceutica Ltd.
15.3.6. Chimerix, Inc.
15.3.7. F. Hoffmann-La Roche Ltd
15.3.8. Gilead Sciences, Inc.
15.3.9. GlaxoSmithKline plc
15.3.10. Merck & Co., Inc.
15.3.11. Moderna Therapeutics, Inc.
15.3.12. Pfizer Inc.
15.3.13. Roche Holding AG
15.3.14. Takeda Pharmaceutical Company Limited
15.3.15. Vical Incorporated
15.3.16. Vistide Pharmaceuticals Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix

List of Figures
FIGURE 1. CYTOMEGALOVIRUS TREATMENT DRUGS MARKET MULTI-CURRENCY
FIGURE 2. CYTOMEGALOVIRUS TREATMENT DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. CYTOMEGALOVIRUS TREATMENT DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CYTOMEGALOVIRUS TREATMENT DRUGS MARKET, FPNV POSITIONING MATRIX, 2024


List of Tables
TABLE 1. CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY NON-NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULINS (IVIG), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PREEMPTIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY UNIVERSAL PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPETENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY HIV/AIDS PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TRANSPLANT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY NEONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 76. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 77. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 79. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 80. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 82. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 83. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 84. CANADA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 89. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 91. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 93. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 94. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 95. MEXICO CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 133. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 134. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 136. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 137. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 139. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 140. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 141. CHINA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 144. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 145. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 147. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 148. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 150. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 151. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 152. INDIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 166. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 167. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 169. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 170. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 172. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 173. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 174. JAPAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 195. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 202. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 205. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 206. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 207. SINGAPORE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 213. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 214. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 216. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 217. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 218. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 222. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 224. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 225. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 227. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 228. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 232. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 233. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 235. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 236. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 238. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 239. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 240. THAILAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 243. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 244. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 246. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 247. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 249. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 250. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 251. VIETNAM CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 264. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 266. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 267. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 269. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 270. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 271. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 272. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 273. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 274. DENMARK CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 277. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 278. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 280. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 281. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 283. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 284. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 285. EGYPT CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 288. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 289. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 291. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 292. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 293. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 294. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD MILLION)
TABLE 295. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 296. FINLAND CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. FRANCE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. FRANCE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 299. FRANCE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 300. FRANCE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 301. FRANCE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 302. FRANCE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 303. FRANCE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 304. FRANCE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 305. FRANCE CYTOMEGALOVIRUS TREATMENT DRUGS MARKET SIZE, BY IMMUNOCOMPROMISED, 2018-2030 (USD

Companies Mentioned

  • AbbVie Inc.
  • AiCuris Anti-infective Cures GmbH
  • AlloVir, Inc.
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Chimerix, Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna Therapeutics, Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited
  • Vical Incorporated
  • Vistide Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Cytomegalovirus Treatment Market - Global Forecast to 2030 - Product Image

Cytomegalovirus Treatment Market - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Cytomegalovirus (CMV) Treatment - Global Strategic Business Report - Product Image

Cytomegalovirus (CMV) Treatment - Global Strategic Business Report

  • Report
  • 384 Pages
  • Global
From
Cytomegalovirus Treatment Market Analysis & Forecast to 2024-2034: Market By Drug Type; By Application; By Distribution Channel; and By Region - Product Image

Cytomegalovirus Treatment Market Analysis & Forecast to 2024-2034: Market By Drug Type; By Application; By Distribution Channel; and By Region

  • Report
  • 200 Pages
  • Global
From
Valganciclovir Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024-2032 - Product Image

Valganciclovir Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024-2032

  • Report
  • 120 Pages
  • Global
From
Cytomegalovirus Infection - Pipeline Insight, 2025 - Product Image

Cytomegalovirus Infection - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.